<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 10-Q
-----------
(Mark One)
|X| Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
FOR THE PERIOD ENDED MARCH 31, 1998
OR
|_| Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
COMMISSION FILE NUMBER: 0-28324
BIOTRANSPLANT INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 04-3119555
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
CHARLESTOWN NAVY YARD, BUILDING 75 THIRD AVENUE
CHARLESTOWN, MASSACHUSETTS 02129
(Address of principal executive offices)
(617) 241-5200
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:
Yes X No
--- ---
As of May 6, 1998, there were 8,578,743 shares of the
Registrant's Common Stock outstanding.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
FORM 10-Q
INDEX
<TABLE>
<CAPTION>
PART I. FINANCIAL INFORMATION
Page No.
--------
<S> <C>
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Condensed Consolidated Balance Sheets as of December 31, 1997
and March 31, 1998 ............................................. 3
Condensed Consolidated Statement of Operations for the three months
ended March 31, 1997 and 1998, and for the period from
inception (March 20, 1990) to March 31, 1998 ................... 4
Condensed Consolidated Statement of Cash Flows for the three months
ended March 31, 1997 and 1998, and for the period from inception
(March 20, 1990) to March 31, 1998 ............................. 5
Notes to Condensed Consolidated Financial Statements ................. 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS ................................... 8
PART II. OTHER INFORMATION
ITEM 1. - 6 ................................................................... 11
SIGNATURES .................................................. 12
</TABLE>
2
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
<TABLE>
CONDENSED CONSOLIDATED BALANCE SHEETS
<CAPTION>
March 31,
December 31, 1998
1997 (Unaudited)
------------------- ----------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 9,784,229 $ 17,524,257
Short-term investments 19,862,617 8,722,257
Prepaid expenses and other current assets 1,238,500 1,051,893
------------------- ----------------
Total current assets 30,885,346 27,298,407
Property and equipment - net 1,003,249 928,294
Long-term investments 1,015,202 1,002,291
Other assets 34,727 26,431
------------------- ----------------
TOTAL ASSETS $ 32,938,524 $ 29,255,423
------------------- ----------------
------------------- ----------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current obligation under capital leases $ 177,667 $ 93,165
Accounts payable 289,535 628,737
Accrued expenses 2,182,216 2,264,542
Deferred revenue 4,125,000 1,750,000
------------------- ----------------
Total current liabilities 6,774,418 4,736,444
------------------- ----------------
Long-term obligation under capital leases 10,042 7,161
------------------- ----------------
Stockholders' equity:
Preferred stock, $.01 par value, authorized 2,000,000 shares; issued and
outstanding - no shares -- --
Common stock, $.01 par value, authorized 25,000,000 shares; issued and outstanding
8,575,390 shares at December 31, 1997 and 8,578,743 shares at March 31, 1998 85,754 85,787
Additional paid-in capital 65,330,483 65,342,145
Accumulated deficit (39,262,173) (40,916,114)
------------------- ----------------
Total stockholders' equity 26,154,064 24,511,818
------------------- ----------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 32,938,524 $ 29,255,423
------------------- ----------------
------------------- ----------------
</TABLE>
The accompanying notes are an integral part of these
condensed consolidated financial statements.
3
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Cumulative
March 31, Since
1997 1998 Inception
------------ ------------ ------------
<S> <C> <C> <C>
Revenues:
License fees $ -- $ -- $ 14,000,000
Research and development 1,250,000 2,375,000 23,750,000
Interest income 404,717 416,583 3,969,461
------------ ------------ ------------
Total revenues 1,654,717 2,791,583 41,719,461
------------ ------------ ------------
Expenses:
Research and development 3,368,243 3,685,581 66,217,034
General and administrative 668,584 754,417 14,663,040
Interest 20,106 5,526 1,755,501
------------ ------------ ------------
Total expenses 4,056,933 4,445,524 82,635,575
------------ ------------ ------------
Net loss $ (2,402,216) $ (1,653,941) $(40,916,114)
------------ ------------ ------------
------------ ------------ ------------
Basic and diluted net loss per
common share $ (0.28) $ (0.19)
------------ ------------
------------ ------------
Weighted average common shares
outstanding 8,561,383 8,578,706
------------ ------------
------------ ------------
</TABLE>
The accompanying notes are an integral part of these
condensed consolidated financial statements.
4
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Cumulative
March 31, Since
1997 1998 Inception
------------ ------------ ------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss $ (2,402,216) $ (1,653,941) $(40,916,114)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 146,924 131,405 3,257,633
Noncash interest expense -- -- 465,477
Noncash expenses related to options and warrants 8,297 8,297 1,160,355
Changes in current assets and liabilities:
Deposits and prepaid expenses 78,017 186,607 (1,051,893)
Accounts payable (75,695) 339,202 628,737
Accrued expenses 21,899 82,325 2,264,541
Deferred revenue 8,000,000 (2,375,000) 1,750,000
------------ ------------ ------------
Net cash provided by (used in) operating activities 5,777,226 (3,281,105) (32,441,264)
------------ ------------ ------------
Cash flows from investing activities:
Purchases of property and equipment (46,092) (56,451) (3,562,732)
Disposal of property and equipment, net -- -- 28,040
Purchases of investments (7,059,691) (1,023,775) (58,274,493)
Proceeds from investments 9,137,589 12,177,045 48,549,944
------------ ------------ ------------
Net cash provided by (used in) investing activities 2,031,806 11,096,819 (13,259,241)
------------ ------------ ------------
Cash flows from financing activities:
Proceeds from convertible notes payable to stockholders -- -- 9,400,000
Payments of obligations under capital leases (108,511) (87,382) (2,093,884)
Proceeds from sale/leaseback of equipment -- -- 771,968
Net proceeds from equipment leases -- -- 1,422,240
Net proceeds from sale of redeemable convertible preferred stock -- -- 25,661,526
Proceeds from sale of common stock 11,392 11,696 28,062,912
------------ ------------ ------------
Net cash provided by (used in) financing activities (97,119) (75,686) 63,224,762
------------ ------------ ------------
Net increase in cash and cash equivalents 7,711,913 7,740,028 17,524,257
Cash and cash equivalents, beginning of period 6,563,957 9,784,229 --
------------ ------------ ------------
Cash and cash equivalents, end of period $ 14,275,870 $ 17,524,257 $ 17,524,257
------------ ------------ ------------
------------ ------------ ------------
Supplemental disclosures and noncash transactions:
Increase in equipment under capital leases $ -- $ -- $ (2,210,270)
------------ ------------ ------------
------------ ------------ ------------
Conversion of convertible notes payable to stockholders and
accrued interest into redeemable convertible preferred stock $ -- $ -- $ 9,905,710
------------ ------------ ------------
------------ ------------ ------------
Issuance of warrants $ -- $ -- $ 741,737
------------ ------------ ------------
------------ ------------ ------------
Interest paid during the period $ 18,770 $ 4,464 $ 1,391,835
------------ ------------ ------------
------------ ------------ ------------
</TABLE>
The accompanying notes are an integral part of these
condensed consolidated financial statements.
5
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Operations and Basis of Presentation
BioTransplant Incorporated (the "Company") was incorporated on March 20,
1990. The Company is developing proprietary pharmaceuticals and organ
transplantation systems which represent a comprehensive approach to inducing
functional tolerance in humans.
The Company is in the development stage and is devoting substantially all of its
efforts toward product research and development and raising capital. The Company
is subject to a number of risks similar to those of other development stage
companies, including dependence on key individuals, competition from larger
companies, the development of commercially usable products, obtaining regulatory
approval for products under development, the development and marketing of
commercial products, and the need to obtain adequate additional financing
necessary to fund the development of its products.
The interim financial statements herein have been prepared by the Company,
without audit, pursuant to the rules and regulations of the Securities and
Exchange Commission ("SEC") and include, in the opinion of management, all
adjustments, consisting of normal, recurring adjustments, necessary for a fair
representation of interim period results. Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations. The results for the interim periods
presented are not necessarily indicative of results to be expected for the
fiscal year or any future period. These condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial
statements and the notes thereto included in the Company's Annual Report on Form
10-K for the year ended December 31, 1997, as filed with the Securities and
Exchange Commission.
2. Cash Equivalents and Investments
Cash equivalents include short-term, highly liquid investments with original
maturities of less than three months from the date of purchase. Short-term
investments consist primarily of corporate notes and securities issued by the
United States Treasury or other United States government agencies with original
maturities of greater than three months and remaining maturities of less than
one year. Long-term investments consist primarily of corporate notes with
remaining maturities of greater than one year. In accordance with Financial
Accounting Standards Board Statement No. 115, "Accounting for Certain
Investments in Debt and Equity Securities", the Company's investments are
classified as held-to-maturity and are stated at amortized cost, which
approximates market value.
The Company held the following investments at December 31, 1997 and March 31,
1998:
<TABLE>
<CAPTION>
December 31, March 31,
1997 1998
----------- -----------
<S> <C> <C>
Short-term:
United States Treasury and Agency Securities
(average maturity of 2 months) $ 2,000,000 $ --
Corporate Bonds (average maturity of 4 months) 16,862,948 7,722,470
Commercial Paper (average maturity of 8 and 5 months) 999,669 999,787
----------- -----------
$19,862,617 $ 8,722,257
----------- -----------
----------- -----------
Long-term:
Corporate Bonds (average maturity of 16 and 13 months) $ 1,015,202 $ 1,002,291
----------- -----------
----------- -----------
</TABLE>
6
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, Continued
(Unaudited)
3. Net Loss Per Common Share
Net loss per common share is based on the weighted average number of common
shares outstanding during the periods presented, in accordance with Financial
Accounting Standards Board Statement No. 128, "Earnings Per Share". Diluted net
loss per common share is the same as basic net loss per common share as the
inclusion of stock issuable pursuant to options and warrants would be
antidilutive.
4. Revenue Recognition
Substantially all of the Company's license and research and development revenues
are derived from two collaborative research arrangements. Annual research and
development payments are recognized on a straight-line basis over the period of
the contract, which approximates when work is performed and costs are incurred.
License fee revenue represents technology transfer fees received for rights to
certain technology of the Company. License fees are recognized as revenue is
earned. Deferred revenue represents amounts received in advance for research and
development. Research and development expenses in the accompanying consolidated
statements of operations include funded and unfunded expenses.
5. Term Note
In September 1997, the Company entered into a term note with a bank, whereby the
Company may borrow up to $500,000 for certain equipment and fixtures during a
specified drawdown period, after which time the outstanding balance will become
payable in 36 equal monthly principal installments plus interest. This term note
bears annual floating interest at the Bank's Prime Rate (8.50% at March 31,
1998) during the drawdown period with an option to convert during the repayment
period to an annual fixed rate at the three month London Interbank Offered Rate
("LIBOR") (5.69% at March 31, 1998) plus 2.25%. This term note is secured by
equipment and fixtures purchased under these borrowings. There were no
borrowings outstanding under this term note at March 31, 1998.
7
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Overview
Since commencement of operations in 1990, the Company has been a development
stage company engaged primarily in the research and development of
proprietary pharmaceuticals and organ transplantation systems which represent
a comprehensive approach to inducing functional tolerance in humans. The
major sources of the Company's working capital have been the proceeds from
sales of equity securities, sponsored research funding and license fees and
capital lease financings. The Company has not generated any revenues from the
sale of products to date, and does not expect to receive any product revenues
for several years. The Company will be required to conduct significant
research, development, testing and regulatory compliance activities that,
together with general and administrative expenses, are expected to result in
significant and increasing operating losses for at least the next several
years.
In 1993, and as amended and restated in September 1995, the Company and
Novartis entered into a collaboration agreement for the development and
commercialization of xenotransplantation products utilizing gene
transduction. Under the agreement, Novartis has committed research funding
through March 1998 of $20.0 million, all of which had been received as of
March 31, 1998, and agreed to pay license fees of $10.0 million, all of which
had been received as of March 31, 1998. The $9.0 million payment from
Novartis which was received during March 1997 was comprised of $6.0 million
in research funding for the gene transduction approach to
xenotransplantation, which has been recognized as revenue on a straight-line
basis over the one-year period from April 1, 1997 to March 31, 1998, and $3.0
million in license fees which was recognized as revenue in April 1997.
Novartis has also agreed to fund certain development and premarketing costs
of such products, portions of which, under certain circumstances, may be
repayable from the Company's operating profits from sales of such products.
In October 1997, the Company and Novartis expanded their relationship in
xenotransplantation by entering into a collaboration and license agreement for
the development and commercialization of xenotransplantation products utilizing
the Company's proprietary mixed bone marrow chimerism technology. Under the
agreement, the Company may receive from Novartis research funding, license fees,
and milestone payments of up to $36.0 million. As of March 31, 1998, research
funding of $3.5 million and license fees of $2.0 million had been received. In
addition to research funding, Novartis will also fund certain development and
premarketing costs of such products. Portions of these costs may be repayable
under certain circumstances.
In October 1995, the Company and MedImmune formed a collaborative research
agreement for the development of products to treat and prevent organ rejection.
MedImmune paid the Company a $2.0 million license fee at the time of execution
of the agreement, and agreed to fund and assume responsibility for clinical
testing and commercialization of BTI-322/MEDI-507 and other related products.
MedImmune has agreed to provide research support and make milestone payments
which could total up to an additional $14.0 million, up to $12.0 million of
which is repayable from royalties on such products.
Results of Operations
Three Months Ended March 31, 1998 and 1997
Revenues increased to $2.8 million for the three months ended March 31, 1998
from $1.7 million for the three months ended March 31, 1997. The increase in
revenues was primarily due to $2.4 million in sponsored research funding from
Novartis during the three months ended March 31, 1998 as a result of the
expansion of the collaboration agreement with Novartis in October 1997, compared
to $1.0 million from Novartis and $250,000 from MedImmune in sponsored research
funding during the three months ended March 31, 1997.
Research and development expenses increased to $3.7 million for the three months
ended March 31, 1998 from $3.4 million for the three months ended March 31,
1997. This increase was primarily due to increases in sponsored research,
research and development staff and associated increases in supplies and support
services.
General and administrative expenses increased to $754,000 for the three months
ended March 31, 1998 from $669,000 for the three months ended March 31, 1997.
This increase was primarily due to increases in outside professional services in
connection with market research and business development.
8
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
Interest income increased to $417,000 for the three months ended March 31, 1998
from $405,000 for the three months ended March 31, 1997. The increase was due
primarily to higher average yields on cash balances available for investment.
Interest expense decreased to $6,000 for the three months ended March 31, 1998
from $20,000 for the three months ended March 31, 1997. The decrease was
primarily due to decreasing balances on existing obligations under capital
leases
As a result of the above factors the Company generated a net loss for the three
months ended March 31, 1998 of $1.7 million, or $0.19 per share, compared to a
net loss of $2.4 million, or $0.28 per share for the three months ended March
31, 1997.
Liquidity and Capital Resources
In May 1996, the Company completed an initial public offering of 3,220,000
shares of common stock at a price of $9.50 per share, and received net proceeds
of approximately $28.0 million. In addition, all outstanding shares of
redeemable convertible preferred stock were automatically converted into
5,202,154 shares of common stock upon the closing of the initial public
offering.
Since its inception and prior to the completion of the Company's initial public
offering, the Company's operations have been funded principally through the net
proceeds of an aggregate of $36.2 million from private placements of equity
securities. The Company has also received $35.5 million from research and
development and collaboration agreements with Novartis, $4.0 million from an
alliance agreement with MedImmune and $2.2 million in equipment lease financing.
The proceeds of the private placements, notes payable and capital leases and
cash generated from the corporate collaborations with Novartis and MedImmune
have been used to fund operating losses of approximately $40.9 million and the
investment of approximately $4.1 million in equipment and leasehold improvements
through March 31, 1998. In September 1997, the Company entered into a term note
with a bank, whereby the Company may borrow up to $500,000 for certain equipment
and fixtures. There were no borrowings outstanding under this term note at March
31, 1998. The Company had no significant commitments as of March 31, 1998 for
capital expenditures.
The Company had cash and cash equivalents and investments of $27.2 million as of
March 31, 1998.
The Company anticipates that its existing funds should be sufficient to fund its
operating and capital requirements as currently planned through at least June
30, 1999. However, the Company's cash requirements may vary materially from
those now planned, due to many factors, including, but not limited to, the
progress of the Company's research and development programs, the scope and
results of preclinical and clinical testing, changes in existing and potential
relationships with corporate collaborators, the time and cost in obtaining
regulatory approvals, the costs involved in obtaining and enforcing patents,
proprietary rights and any necessary licenses, the ability of the Company to
establish development and commercialization capacities or relationships, the
costs of manufacturing and other factors, including those discussions below
under "Factors Affecting Future Operating Results".
The Company expects to incur substantial additional costs, including costs
related to research and development activities, preclinical studies, clinical
trials, obtaining regulatory approvals, manufacturing and the expansion of its
facilities. The Company will need to raise substantial additional funds, through
additional financings including public or private equity offerings and
collaborative arrangements with corporate partners. There can be no assurance
that funds will be available on terms acceptable to the Company, if at all. If
adequate funds are not available, the Company may be required to delay, scale
back or eliminate certain of its product development programs or to license to
others the right to commercialize products or technologies that the Company
would otherwise seek to develop and commercialize itself, any of which would
have a material and adverse effect on the Company.
The Company is evaluating Year 2000 issues and their potential impact on its
information systems and computer technologies. All evaluation costs will be
expensed as incurred. Year 2000 issues are not expected to have a significant
impact on the Company's ongoing results of operations.
FACTORS AFFECTING FUTURE OPERATING RESULTS
This Quarterly Report to Stockholders on Form 10-Q contains forward-looking
statements. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "intends," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that could
cause the Company's actual results to differ materially from those indicated by
such forward-looking statements. These factors include, without limitation,
those set forth below and elsewhere in this Quarterly Report to Stockholders on
Form 10-Q and in the Section titled "Business - Factors That May Affect Results"
in the Company's Annual Report to Stockholders on Form 10-K for the year ended
December 31, 1997, as filed with the Securities and Exchange Commission, which
Section is incorporated herein by reference.
9
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
The Company is in the early development stage and has been engaged, to date,
primarily in organizational and research and development activities. The Company
has not yet completed the development of, or conducted significant human testing
with respect to, any product. In particular, the Company's AllomuneTM and
XenomuneTM Systems are based upon approaches which are novel and, to the
Company's knowledge, have never been achieved in humans, including by the
Company. There can be no assurance that any of the Company's products will be
successfully developed, prove to be safe and efficacious in clinical trials,
meet applicable regulatory standards, obtain required regulatory approvals, be
capable of being produced in commercial quantities at reasonable costs or be
successfully marketed.
The Company has a substantial accumulated deficit. The Company expects to incur
losses for at least the next several years and that such losses will increase as
the Company expands its research and development activities. The Company will
require substantial additional funds for its research and product development
programs, operating expenses, the pursuit of regulatory approvals and expansion
of its production, sales and marketing capabilities. Adequate funds for these
purposes, whether through equity or debt financings, collaborative or other
arrangements with corporate partners or from other sources, may not be available
when needed or on terms acceptable to the Company. Insufficient funds could
require the Company to delay, scale back or eliminate certain of its research
and product development programs or to license to third parties to commercialize
products or technologies that the Company would otherwise develop or
commercialize itself.
The Company's strategy for development and commercialization of its products
entails entering into arrangements with third parties. There can be no assurance
that the Company will be able to maintain its existing arrangements or establish
additional arrangements that the Company deems necessary or acceptable to
develop and commercialize its potential pharmaceutical products or that such
arrangements will be successful. In addition, the Company is entitled to receive
royalties on MEDI-500, a product proprietary to MedImmune, and any such
royalties are wholly dependent on the efforts of MedImmune to develop and market
such product. If any of the Company's strategic partners were to breach or
terminate its agreement with the Company or otherwise fail to conduct its
collaborative activities successfully in a timely manner, such delay or
termination could have a material adverse effect on the Company's business,
financial condition and results of operations.
Proprietary rights relating to the products of BioTransplant will be protected
from unauthorized use by third parties only to the extent that they are covered
by valid and enforceable patents or are maintained in confidence as trade
secrets. There may be pending or issued third-party patents relating to the
products of BioTransplant and BioTransplant may need to acquire licenses to, or
to contest the validity of, any such patents. It is likely that significant
funds would be required to defend any claim that BioTransplant infringes a
third-party patent. There can be no assurance that any license required under
any such patent would be made available.
Other factors that may affect the Company's future operating results include the
inherent risk of product liability claims which may result from the testing,
marketing and sale of human therapeutic products, the Company's fluctuations in
quarterly operating results, the Company's ability to continue to attract and
retain qualified management and scientific staff, risks associated with the
regulatory approval process, and its ability to anticipate or respond adequately
to rapid and significant technological changes that may develop in the field of
human therapeutic products.
10
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Response: None
ITEM 2. CHANGES IN SECURITIES
Response: None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Response: None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Response: None
ITEM 5. OTHER INFORMATION
Response: None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a) Exhibits
27 Financial Data Schedule.
b) Reports on Form 8-K
None.
11
<PAGE>
BIOTRANSPLANT INCORPORATED AND SUBSIDIARY
(A Development Stage Company)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BioTransplant Incorporated
(Registrant)
Date: May 12, 1998 /s/ Elliot Lebowitz
----------------------------------------------
Elliot Lebowitz
President and Chief Executive Officer
(Principal Executive Officer)
/s/ Richard V. Capasso
----------------------------------------------
Richard V. Capasso
Vice President, Finance and Treasurer
(Principal Financial and Accounting Officer)
12
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED BALANCE SHEET OF MARCH 31,1998 AND THE CONDENSED CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31,1998.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 17,524,257
<SECURITIES> 8,722,257
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 27,298,407
<PP&E> 4,122,239
<DEPRECIATION> 3,193,945
<TOTAL-ASSETS> 29,255,423
<CURRENT-LIABILITIES> 4,736,444
<BONDS> 0
0
0
<COMMON> 85,787
<OTHER-SE> 65,342,145
<TOTAL-LIABILITY-AND-EQUITY> 29,255,423
<SALES> 0
<TOTAL-REVENUES> 2,791,583
<CGS> 0
<TOTAL-COSTS> 4,445,524
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 5,526
<INCOME-PRETAX> (1,653,941)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,653,941)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,653,941)
<EPS-PRIMARY> (0.19)
<EPS-DILUTED> (0.19)
</TABLE>
